Drug intelligence / Profile preview

HX008 + niraparib

Development stage: Preclinical
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

HX008 + niraparib is a combination therapy consisting of HX008, a PD-1 inhibitor (immune checkpoint inhibitor), and niraparib, a PARP (Poly ADP-ribose polymerase) inhibitor. This combination represents a dual approach to cancer treatment, combining immunotherapy with targeted therapy. Clinical trials have shown promising efficacy and tolerable safety profile in metastatic breast cancer patients with germline BRCA1/2 mutations.

Targets

PARP1 (Poly (adp-ribose) polymerase 1)Pol II (RNA polymerase II elongation factors)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on HX008 + niraparib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HX008 + niraparib.

Explore the full profile